Kurt Brunden, PhD
Research Associate Professor
Scientific Director, Marian S. Ware Alzheimer and Benaroya Parkinson's Disease Drug Discovery Programs
Mailing Address:
| University of Pennsylvania School of Medicine |
||
| 3600 Spruce Street, 640B Maloney Building / 4283 |
||
| Office:
215-615-5262 |
Lab: 215-662-3292 |
Fax: 215-349-5909 |
| Email: kbrunden@mail.med.upenn.edu |
||
As Director of CNDR Drug Discovery, Dr. Brunden oversees a research team that is responsible for translating basic research discoveries made within CNDR into programs that will ultimately lead to new therapeutic treatments for neurodegenerative disease. This encompasses a variety of research activities, including further validation of putative drug targets, development of high-throughput assays to allow evaluation of small molecule compounds to such drug targets, in vitro and in vivo pharmacological characterization of active compounds identified during compound screening, and medicinal chemistry refinement of prototype lead compounds to improve drug efficacy, pharmacokinetics, and safety.
Select Publications
Kim, ML, Zhang, B, Mills, IP, Milla, ME, Brunden, KR and Lee, VM-Y (2008) Effects of TNFα-converting enzyme inhibition in amyloid β production and APP processing in vitro and in vivo. J. Neurosci. 28:12052-12061.
Brunden KR, Trojanowski, JQ and Lee VM (2008) Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J. Alzheimers Dis. 14(4):393-399.
Huck BR, Llamas L, Robarge MJ, Dent TX, Song J, Hodnick WF, Crumrine C, Stricker-Krongrad A, Harrington J, Brunden KR and Bennani YL (2006) The design and synthesis of a tricyclic single-nitrogen scaffold that serves as a 5-HT2C receptor agonist. Bioorganic Med. Chem. Letters. 16:4130-4134.
Murphy SM, Palmer M, Poole MF, Padegimas L, Hunady K, Danzig J, Gill S, Gill R, Ting A, Sherf B, Brunden K and Stricker-Krongrad A (2006) Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel. J. Pharmacol. Toxicol. Methods. 54:42-55.
Brunden KR, Sherf BA and Harrington, JJ (2005) The Application of RAGE and GECKO in Cell-based Target Discovery Screens. Pharmacogenomics 6:383-39.